229 related articles for article (PubMed ID: 10389920)
1. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis.
Wymenga AN; van der Graaf WT; Hofstra LS; Spijkervet FK; Timens W; Timmer-Bosscha H; Sluiter WJ; van Buuren AH; Mulder NH; de Vries EG
Clin Cancer Res; 1999 Jun; 5(6):1363-8. PubMed ID: 10389920
[TBL] [Abstract][Full Text] [Related]
2. A new in vitro assay for quantitation of chemotherapy-induced mucositis.
Wymenga AN; van der Graaf WT; Spijkervet FL; Timens W; Timmer-Bosscha H; Sluiter WJ; de Vries EG; Mulder NH
Br J Cancer; 1997; 76(8):1062-6. PubMed ID: 9376267
[TBL] [Abstract][Full Text] [Related]
3. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Choi K; Lee SS; Oh SJ; Lim SY; Lim SY; Jeon WK; Oh TY; Kim JW
Clin Nutr; 2007 Feb; 26(1):57-62. PubMed ID: 16949180
[TBL] [Abstract][Full Text] [Related]
5. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Bhalla KN; Kumar GN; Walle UK; Ibrado AM; Javed T; Stuart RK; Reed C; Arbuck SG; Walle T
Clin Cancer Res; 1999 Jul; 5(7):1723-30. PubMed ID: 10430075
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Prince HM; Regester G; Gates P; Jablonskis L; Seymour JF; Lillie K; West R; Wolf M; Januszewicz H; Belford D
Biol Blood Marrow Transplant; 2005 Jul; 11(7):512-20. PubMed ID: 15983551
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.
Meropol NJ; Somer RA; Gutheil J; Pelley RJ; Modiano MR; Rowinsky EK; Rothenberg ML; Redding SW; Serdar CM; Yao B; Heard R; Rosen LS
J Clin Oncol; 2003 Apr; 21(8):1452-8. PubMed ID: 12697866
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
10. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
12. Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.
Foncuberta MC; Cagnoni PJ; Brandts CH; Mandanas R; Fields K; Derigs HG; Reed E; Sonis ST; Fay J; LeVeque F; Pouillart P; Schrezenmeier H; Emmons R; Thiel E;
J Immunother; 2001; 24(4):384-8. PubMed ID: 11565840
[TBL] [Abstract][Full Text] [Related]
13. [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
Fukazawa M; Kawaguchi H; Shigematsu H; Koga C; Mori E; Nishimura S; Nakamura Y; Satou S; Sawamura K; Kashiwaba K; Ohno S
Gan To Kagaku Ryoho; 2012 Mar; 39(3):395-8. PubMed ID: 22421766
[TBL] [Abstract][Full Text] [Related]
14. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
17. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
18. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial.
Karthaus M; Rosenthal C; Huebner G; Paul H; Elser C; Hertenstein B; Krauter J; Scharmann T; Geissler RG; Heil G; Ganser A
Bone Marrow Transplant; 1998 Oct; 22(8):781-5. PubMed ID: 9827976
[TBL] [Abstract][Full Text] [Related]
19. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.
Sonis ST; Lindquist L; Van Vugt A; Stewart AA; Stam K; Qu GY; Iwata KK; Haley JD
Cancer Res; 1994 Mar; 54(5):1135-8. PubMed ID: 8118793
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies.
Sorensen JB; Skovsgaard T; Bork E; Damstrup L; Ingeberg S
Cancer; 2008 Apr; 112(7):1600-6. PubMed ID: 18300265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
